CAR T-cell therapies are showing huge promise as the future standard of care in hard-to-treat patients with relapsed or refractory large B cell lymphoma (LBCL) – but not every product wins. Speaking at the 63rd ASH Annual Meeting and Exposition, Associate Professor Manali Kamdar presented the results of the phase 3 study of lisocabtagene maraleucel ...
Can CAR T-cell therapy now move to 2nd line treatment in lymphoma?
By Mardi Chapman
10 Jan 2022